For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS)
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),